PriceTargets.com logo

Nuwellis - NUWE Stock Price Target and Predictions

  • Consensus Rating: Strong Buy
  • Consensus Price Target: $17.00
  • Forecasted Upside: 1,639.13%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 1 Strong Buy Ratings
$0.98 As of 12/17/2024 01:00 AM ET
▼ -0.21 (-17.68%)

This chart shows the closing price for NUWE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Nuwellis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NUWE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NUWE

Analyst Price Target is $17.00
▲ +1,639.13% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Nuwellis in the last 3 months. The average price target is $17.00, with a high forecast of $17.00 and a low forecast of $17.00. The average price target represents a 1,639.13% upside from the last price of $0.98.

This chart shows the closing price for NUWE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Strong Buy

The current consensus among 2 contributing investment analysts is to buy (strong buy) stock in Nuwellis. This rating has held steady since October 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/18/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/18/2024

Latest Recommendations

  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/13/2024Roth MkmReiterated RatingBuy ➝ Buy$17.00 ➝ $17.00
7/29/2024Roth CapitalUpgradeStrong-Buy
7/29/2024Roth MkmInitiated CoverageBuy$17.00
11/8/2023LADENBURG THALM/SH SHReiterated RatingBuy ➝ Neutral
1/4/2023Maxim GroupLower Target$2,625.00 ➝ $875.00
11/10/2021Maxim GroupLower TargetPositive ➝ Buy$42,000.00 ➝ $21,000.00
9/7/2021Lake Street CapitalInitiated CoverageBuy$31,500.00
(Data available from 12/18/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/22/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2024
  • 0 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2024
  • 1 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Nuwellis logo
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Read More

Today's Range

Now: $0.98
Low: $0.97
High: $1.18

50 Day Range

MA: $1.55
Low: $0.98
High: $2.81

52 Week Range

Now: $0.98
Low: $0.97
High: $30.10

Volume

694,151 shs

Average Volume

907,488 shs

Market Capitalization

$4.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32

Frequently Asked Questions

What sell-side analysts currently cover shares of Nuwellis?

The following sell-side analysts have issued stock ratings on Nuwellis in the last twelve months: Roth Capital, and Roth Mkm.
View the latest analyst ratings for NUWE.

What is the current price target for Nuwellis?

0 Wall Street analysts have set twelve-month price targets for Nuwellis in the last year. Their average twelve-month price target is $17.00, suggesting a possible upside of 1,639.1%. Roth Mkm has the highest price target set, predicting NUWE will reach $17.00 in the next twelve months. Roth Mkm has the lowest price target set, forecasting a price of $17.00 for Nuwellis in the next year.
View the latest price targets for NUWE.

What is the current consensus analyst rating for Nuwellis?

Nuwellis currently has 1 buy rating and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Strong Buy."
View the latest ratings for NUWE.

What other companies compete with Nuwellis?

Other companies that are similar to Nuwellis include Microbot Medical, NeurAxis, Nephros, Innovative Eyewear and Inspira Technologies Oxy B.H.N.. Learn More about companies similar to Nuwellis.

How do I contact Nuwellis' investor relations team?

Nuwellis' physical mailing address is 12988 VALLEY VIEW ROAD, EDEN PRAIRIE MN, 55344. The company's listed phone number is (952) 345-4200 and its investor relations email address is [email protected]. The official website for Nuwellis is www.nuwellis.com. Learn More about contacing Nuwellis investor relations.